Swiss pharmaceutical giant Roche has secured global rights to Alector’s prominent preclinical Parkinson’s disease candidate, AL050, in a lucrative transaction…
Read More

Swiss pharmaceutical giant Roche has secured global rights to Alector’s prominent preclinical Parkinson’s disease candidate, AL050, in a lucrative transaction…
Read More